A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

August 31, 2029

Conditions

High Grade GliomaReplication Repair Deficient

Interventions

DRUG

Nivolumab

All patients will be administered Nivolumab with or without radiation

RADIATION

Radiation

Trial Locations (1)

RECRUITING

Hospital for Sick Children, Toronto

All Listed Sponsors

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Anti Cancer Fund

UNKNOWN

lead

Daniel Morgenstern

OTHER